PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsOlopatadine
Pataday twice daily relief, Opatanol(olopatadine)
Olopatadine, Opatanol, Pataday, Ryaltris (olopatadine) is a small molecule pharmaceutical. Olopatadine was first approved as Pataday twice daily relief on 1996-12-18. It is used to treat allergic conjunctivitis in the USA. It has been approved in Europe to treat allergic conjunctivitis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
Olopatadine, Pataday (discontinued: Olopatadine, Patanase)
Combinations
Ryaltris
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mometasone furoate
+
Olopatadine hydrochloride
Tradename
Company
Number
Date
Products
RYALTRISGLENMARK SPECLTN-211746 RX2022-01-13
1 products, RLD, RS
Olopatadine hydrochloride
Tradename
Company
Number
Date
Products
PATADAY TWICE DAILY RELIEFAlcon ResearchN-020688 OTC1996-12-18
1 products, RLD, RS
PATADAY ONCE DAILY RELIEFAlcon ResearchN-021545 OTC2004-12-22
1 products, RLD, RS
PATADAY ONCE DAILY RELIEFAlcon ResearchN-206276 OTC2015-01-30
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cvs eye allergy itch reliefANDA2021-04-27
eye allergy itch and redness reliefANDA2024-11-12
eye allergy itch reliefANDA2024-11-12
olopatadineANDA2024-03-25
olopatadine hclANDA2024-05-20
olopatadine hydrochlorideANDA2024-10-22
olopatadine hydrochloride ophthalmic solutionANDA2024-11-12
once daily reliefANDA2023-08-06
patadayNew Drug Application2011-01-05
pataday once daily reliefNew Drug Application2023-12-15
Show 5 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic conjunctivitisEFO_0007141D003233H10.44
pruritusHP_0000989D011537L29
inflammationMP_0001845D007249—
allergic rhinitis perennialEFO_1001417D012221J30.89
facial dermatoses—D005148—
foot dermatoses—D005533—
hand dermatoses—D006229—
scalp dermatoses—D012536—
leg dermatoses—D007868—
Agency Specific
FDA
EMA
Expiration
Code
MOMETASONE FUROATE / OLOPATADINE HYDROCHLORIDE, RYALTRIS, GLENMARK SPECIALTY
2025-01-13NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Mometasone Furoate / Olopatadine Hydrochloride, Ryaltris, Glenmark Specialty
116792102038-09-03DP
90789232034-09-04DPU-3297
93704832034-09-04DP
97507542034-09-04DPU-3297
99371892034-09-04DP
100164432034-09-04U-3297
103765262034-09-04DP
105178802034-09-04DPU-3297
105489072034-09-04U-3297
105616722034-09-04DP
106465002034-09-04U-3297
107585502034-09-04U-3296
107656862034-09-04U-3295
114001012034-09-04U-3297
Olopatadine Hydrochloride, Pataday Once Daily Relief, Alcon Labs Inc
87911542032-05-19DPU-1680
95330532032-05-19DP
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AC: Antiallergic nasal preparations for topical use, excl. corticosteroids
— R01AC08: Olopatadine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX09: Olopatadine
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ConjunctivitisD003231HP_0000509H101—710—18
Allergic conjunctivitisD003233EFO_0007141H10.441—710—18
RhinitisD012220EFO_0008521J31—125—8
Allergic rhinitisD065631—J30.9—124—7
Allergic rhinitis seasonalD006255EFO_0003956J30——12—3
Allergic rhinitis perennialD012221EFO_1001417J30.89——11—2
Vasomotor rhinitisD012223EFO_0007533J30.0———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOlopatadine
INNolopatadine
Description
2-[11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid is a heterotricyclic compound.
Classification
Small molecule
Drug classtricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
Identifiers
PDB—
CAS-ID113806-05-6
RxCUI—
ChEMBL IDCHEMBL1189432
ChEBI ID—
PubChem CID5281071
DrugBankDB00768
UNII IDD27V6190PM (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Olopatadine – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Olopatadine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 941 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
8,789 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use